BL22

(redirected from GCR-3888)
Also found in: Wikipedia.

BL22

A 63-kDa anti-CD22 recombinant immunotoxin, containing truncated Pseudomonas exotoxin and variable domains from an anti-CD22 antibody. It was effective against hairy cell leukaemia in phase-II trials of patients who had relapse less than 4 years after cladribine therapy.
References in periodicals archive ?
1 /PRNewswire-FirstCall/ -- Cambridge Antibody Technology (LONDON: CAT) ; today announces the acquisition of product candidates GCR-3888 and GCR-8015 from Genencor, a subsidiary of Danisco, based in Palo Alto, California.
CAT intends to file an Investigational New Drug (IND) application for GCR- 8015 in various CD22 positive B-cell malignancies, including NHL and CLL, following a period of manufacturing development which is expected to be complete by the end of 2006 and to support the NCI's ongoing development of GCR-3888 in HCL and pediatric acute lymphoblastic leukemia (pALL).
Genencor's immunotoxin program consists of GCR-3888 and GCR-8015, both of which target hematological malignancies.
Cambridge Antibody Technology (Cambridge, England) acquired product candidates GCR-3888 and GCR-8015 from Genencor (Palo Alto, CA).
GCR-3888 and GCR-8015 were discovered and initially developed by the National Cancer Institute (NCI), which is part of the United States National Institutes of Health (NIH).
The NCI has demonstrated significant efficacy of GCR-3888 in a Phase I clinical trial in HCL.
CAT intends to file an Investigational New Drug application for GCR-8015 in various CD22 positive B-cell malignancies, including NHL and CLL, following a period of manufacturing development which is expected to be complete by the end of 2006 and to support the NCI's ongoing development of GCR-3888 in HCL and pediatric acute lymphoblastic leukemia (pALL).
GCR-3888 is an immunotoxin fusion protein between a murine anti-CD22 disulphide-linked Fv antibody fragment (dsFv) and the Pseudomonas exotoxin PE38, and GCR-8015 is an optimized version of GCR-3888 with increased affinity for CD22.
GCR-3888 has demonstrated the potential opportunity from utilizing this immunotoxin approach in HCL and we look forward to exploring the mechanism in a wider range of B-cell malignancies, including NHL and CLL, and to working in collaboration with the NCI.
The two proteins, GCR-3888 (formerly BL22) and GCR-8015 (formerly HA22), are recombinant immunotoxins that specifically target cancers derived from B-cells that express the CD22 antigen.